Incyte: Acquisition and Strong Pipeline Drive Stock at a Record Volume

The US biotech company sees a massive volume spike from the acquisition of Vega Therapeutics. The broad diversification strategy successfully mitigates the risk of the upcoming patent loss in 2028. Strong growth outside of the core product opens up The biopharma company Incyte operates at the intersection of highly attractive future markets and specializes in innovative medicines in the fields of hematology, oncology, and autoimmune diseases. In an aging global population, the company addresses the global megatrend of personalized...